Back to top
more

MEDIFAST (MED)

(Delayed Data from NYSE)

$13.19 USD

13.19
144,148

+0.16 (1.23%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $13.20 +0.01 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 27% (180 out of 246)

Industry: Food - Miscellaneous

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is MEDIFAST INC (MED) Outperforming Other Consumer Staples Stocks This Year?

by Zacks Equity Research

Is (MED) Outperforming Other Consumer Staples Stocks This Year?

Zacks Equity Research

Here's Why Medifast (MED) is Likely to Sustain Solid Run in 2021

by Zacks Equity Research

Medifast (MED) has been benefiting from strength in OPTAVIA along with a focus on core growth strategies even amid the pandemic.

Zacks Equity Research

Mondelez (MDLZ) Gains on Effective Saving Efforts & Buyouts

by Zacks Equity Research

Mondelez (MDLZ) is benefiting from its impressive savings plan and brand-building efforts. However, unfavorable currency rates are headwinds.

Zacks Equity Research

General Mills (GIS) Q2 Earnings & Sales Top Estimates, Up Y/Y

by Zacks Equity Research

General Mills' (GIS) second-quarter fiscal 2021 earnings and sales increase year over year. Results reflect rising demand stemming from increased at-home consumption amid the pandemic.

Zacks Equity Research

McCormick (MKC) Benefits From Brand Strength, Saving Plans

by Zacks Equity Research

McCormick (MKC) is witnessing higher demand thanks to increased-at home consumption amid COVID-19. Also, the company's lucrative acquisitions are worth mentioning.

Zacks Equity Research

Smucker (SJM) Unveils Strategic Growth Pillars, Retains View

by Zacks Equity Research

Smucker (SJM) lays down four pillars of operational priorities for the next 12-18 months to drive growth. Also, the company provides long-term financial targets.

Sanghamitra Saha headshot

5 Top-Ranked Stocks Empowered by DuPont Analysis

by Sanghamitra Saha

Have more faith in DuPont analysis than simple ROE calculation and bet on these five stocks.

Zacks Equity Research

United Natural's (UNFI) Q1 Earnings Miss Estimates, Sales Up

by Zacks Equity Research

United Natural's (UNFI) first-quarter fiscal 2021 results reflect higher sales, courtesy of robust consumer demand and cross-selling benefits. Also, earnings increase year over year.

Zacks Equity Research

Is MEDIFAST INC (MED) Stock Outpacing Its Consumer Staples Peers This Year?

by Zacks Equity Research

Is (MED) Outperforming Other Consumer Staples Stocks This Year?

Zacks Equity Research

Medifast (MED) Up 30.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Medifast (MED) Up More Than 75% YTD: Will Momentum Stay?

by Zacks Equity Research

Medifast (MED) has been gaining on robust performance of OPTAVIA. Also, the company has certain planned investments for growth, though they are likely to affect margins.

Zacks Equity Research

Medifast (MED) Q3 Earnings Surpass Estimates, Increase Y/Y

by Zacks Equity Research

Medifast's (MED) third-quarter 2020 results reflect increased earnings and sales. Robust OPTAVIA performance, courtesy of rise in active earning coaches, fuels results.

Zacks Equity Research

Medifast (MED) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Medifast (MED) delivered earnings and revenue surprises of 16.87% and 10.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's How Medifast (MED) Looks Just Ahead of Q3 Earnings

by Zacks Equity Research

Medifast's (MED) third-quarter results are likely to reflect gains from consumers' increased inclination toward health products amid the pandemic. However, high costs are a concern.

Zacks Equity Research

Mondelez (MDLZ) Queued for Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Higher demand in developed markets amid COVID-19 is likely to get reflected in Mondelez's (MDLZ) third-quarter 2020 numbers. However, escalated costs are a concern.

Zacks Equity Research

Estee Lauder (EL) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Adverse impacts of coronavirus-induced temporary store closures and sluggishness in travel retail are likely to get reflected in Estee Lauder's (EL) first-quarter fiscal 2021 performance.

Zacks Equity Research

Here's How Pilgrim's Pride (PPC) Looks Ahead of Q3 Earnings

by Zacks Equity Research

Macroeconomic headwinds in Mexico and soft demand in foodservice channels are likely to get reflected in Pilgrim's Pride's (PPC) third-quarter performance. However, favorable inputs costs bode well.

Zacks Equity Research

Things You Need to Know Before Newell's (NWL) Q3 Earnings

by Zacks Equity Research

Despite uncertain COVID-19 impacts, Newell's (NWL) Q3 results are likely to have gained from robust consumption patterns, strong e-commerce sales and the Project FUEL plan.

Zacks Equity Research

Here's How Kraft Heinz (KHC) Looks Ahead of Q3 Earnings

by Zacks Equity Research

Increased demand owing to higher at-home consumption amid the coronavirus outbreak is likely to get reflected in Kraft Heinz's (KHC) third-quarter 2020 performance.

Zacks Equity Research

Here's How Kimberly-Clark (KMB) Looks Ahead of Q3 Earnings

by Zacks Equity Research

Drab sales in the K-C Professional unit due to the pandemic are likely to get reflected in Kimberly-Clark's (KMB) third-quarter results. Nonetheless, its robust cost-saving efforts are yielding.

Zacks Equity Research

Medifast Gains on Strength in OPTAVIA, Cost Concerns Stay

by Zacks Equity Research

Medifast's (MED) OPTAVIA lifestyle solution bodes well amid evolving consumer interests in health and wellness. However, rising costs are a concern.

Zacks Equity Research

Why Medifast (MED) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Medifast (MED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Helen of Troy (HELE) Earnings & Sales Beat Estimates in Q2

by Zacks Equity Research

Helen of Troy's (HELE) second-quarter fiscal 2021 results reflect better-than-expected sales and earnings on strength across all segments, along with gains in online business.

Zacks Equity Research

Is MEDIFAST INC (MED) Outperforming Other Consumer Staples Stocks This Year?

by Zacks Equity Research

Is (MED) Outperforming Other Consumer Staples Stocks This Year?

Zacks Equity Research

Lamb Weston (LW) Q1 Earnings Top Estimates, Sales Fall Y/Y

by Zacks Equity Research

Lamb Weston's (LW) first-quarter fiscal 2021 results reflect lower earnings and sales due to soft demand in foodservice channel and elevated costs associated with COVID-19.